Piper Jaffray analyst Edward Tenthoff raised his price target for Crispr Therapeutics to $67 to reflect more value to the company's pipeline. The stock closed yesterday up 4% to $53.70. First-in-man Crisper data will be an important milestone, Tenthoff tells investors in a research note. He believes the company's cash of $362M is enough to conduct a CTX001 beta thalassemia study this year. First-in-man CTX001 data will serve as an important driver and set up potential "rapid approval" in beta-thal by 2020 and sickle cell disease by 2021 with "blockbuster" sales potential, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Crispr Therapeutics.

Meeting to be held in San Francisco on April 24 hosted by Mizuho.